Bruinstroop E, et al. - This is the first study evaluating the efficacy and determinants of success of an insulin-to-liraglutide switch in obese patients with type 2 diabetes. In this retrospective study, all consecutive patients that underwent an insulin-to-liraglutide switch during routine medical care (January 2009–February 2015) were involved. Researchers reported that the majority of patients continued liraglutide after a switch from insulin therapy with on average no change in glycemic control and reduction of body weight. They suggested that HbA1c levels at baseline, duration of insulin therapy, and duration of diabetes were predictive of reaching glycemic control on liraglutide alone. In current practice, this also indicated which patients on insulin can reduce their insulin dose after adding a glucagon-like peptide 1 (GLP-1) receptor agonist.